<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04267679</url>
  </required_header>
  <id_info>
    <org_study_id>GL-2020</org_study_id>
    <nct_id>NCT04267679</nct_id>
  </id_info>
  <brief_title>Cannabidiol for Anxiety</brief_title>
  <official_title>Prospective Evaluation of Cannabidiol (CBD) on Anxiety: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CB2 Insights</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Green Lotus Hemp</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CB2 Insights</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot trial seeks to investigate the effect of 25 mg full-spectrum CBD soft gel capsules
      (up to a total dosage of 100mg per day) on individuals with diagnosed anxiety. All
      participants will take CBD soft gel capsules for 12 weeks, and will be assessed at 6 weeks
      and 12 weeks post-enrollment using measures of anxiety, sleep and perception of change.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Generalized Anxiety Disorder 7-item scale</measure>
    <time_frame>12 weeks</time_frame>
    <description>The Generalized Anxiety Disorder 7-item scale is one of the most frequently used, validated self-reported questionnaires that is used to screen for, diagnose, and assess severity of generalized anxiety disorder.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perception of change</measure>
    <time_frame>12 weeks</time_frame>
    <description>Participants will complete the Patients' Global Impression of Change (PGIC) scale at each follow-up visit, which has been regarded as an important self-reported indicator of change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protocol Compliance</measure>
    <time_frame>12 weeks</time_frame>
    <description>Participants will self-report their intervention compliance using a simple log that will be provided to them at their enrollment visit and will be asked to bring their CBD log to every follow-up visit. Participants will also self-report any medical cannabis or opioid usage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep quality</measure>
    <time_frame>12 weeks</time_frame>
    <description>Participants will be asked whether they believe that the CBD intervention has impacted their sleep quality. They will be asked to complete a short 2-question survey.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>Cannabidiol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take 25 mg full-spectrum CBD soft gel capsules (2 to 4 per day) for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol</intervention_name>
    <description>25 mg full-spectrum CBD soft gel capsules</description>
    <arm_group_label>Cannabidiol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Male or female patients 18 years of age or older with a GAD-7 score of 10 or greater

          2. Presenting to a participating clinic for initial evaluation for a medical cannabis
             card

          3. Willingness to abstain from the use of all other cannabis products for the trial
             period (3 months)

          4. Not pregnant or planning to become pregnant during the trial period (3 months)

          5. Not breastfeeding or planning to breastfeed during the trial period (3 months)

          6. No history of cannabis use within 4 weeks of enrollment

          7. No history of lifetime cannabis use disorder or other substance use disorders (except:
             tobacco use disorder)

          8. No history of lifetime daily cannabis use

          9. No family history of psychosis (e.g., bipolar disorder or schizophrenia)

         10. No history of adverse reactions to cannabis

         11. No recent changes to prescribed anxiety medications (within the last 1 month)

         12. Provision of informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alisha Garibaldi, MSc</last_name>
    <phone>5195020679</phone>
    <email>alisha.garibaldi@cb2insights.com</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 6, 2020</study_first_submitted>
  <study_first_submitted_qc>February 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epidiolex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

